Listen
FLUCELVAX (influenza vaccine (surface antigen, inactivated, prepared in cell cultures)) - Influenza vaccine
Reason for request
Summary of opinion
Favourable opinion for reimbursement in the prophylaxis of influenza in adults and children from 2 years of age and in accordance with the current vaccination recommendations (HAS opinion of 6 February 2025).
Clinical Benefit
| Substantial |
The Committee considers that the clinical benefit of FLUCELVAX (influenza vaccine (surface antigen, inactivated, prepared in cell cultures)) is substantial in the prophylaxis of influenza in adults and children from 2 years of age in accordance with the current HAS vaccination recommendations dating from 6 February 2025. |
Clinical Added Value
| no clinical added value |
The change from tetravalent to trivalent is not of a nature to modify the clinical added value. The Transparency Committee considers that FLUCELVAX (influenza vaccine (surface antigen, inactivated, prepared in cell cultures)) provides no clinical added value (CAV V), in adults and children from 2 years of age for whom vaccination is recommended, compared to the other vaccines recommended in the prevention of seasonal influenza. |
